Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand?

Clinical Rheumatology, Journal Year: 2022, Volume and Issue: 41(5), P. 1603 - 1609

Published: April 5, 2022

Language: Английский

---

Current concepts regarding Graves’ orbitopathy

Journal of Internal Medicine, Journal Year: 2022, Volume and Issue: 292(5), P. 692 - 716

Published: May 23, 2022

Graves' orbitopathy (GO) is an orbital autoimmune disorder and the main extrathyroidal manifestation of disease, most common cause hyperthyroidism. GO affects about 30% patients, although fewer than 10% have severe forms requiring immunosuppressive treatments. Management requires a multidisciplinary approach. Medical therapies for active moderate-to-severe (traditionally, high-dose glucocorticoids) often provide unsatisfactory results, subsequently surgeries are needed to cure residual manifestations. The aim this review updated overview current concepts regarding epidemiology, pathogenesis, assessment, treatment GO, present emerging targeted therapeutic perspectives. Original articles, clinical trials, systematic reviews, meta-analyses from 1980 2021 were searched using following terms: orbitopathy, thyroid eye glucocorticoids, radiotherapy, rituximab, cyclosporine, azathioprine, teprotumumab, TSH-receptor antibody, smoking, hyperthyroidism, hypothyroidism, thyroidectomy, radioactive iodine, antithyroid drugs. Recent studies suggest secular trend toward milder phenotype GO. Standardized assessment at clinic allows better general management plan. Treatment still relies in cases on systemic-mainly intravenous-glucocorticoids as monotherapy or combination with other therapies-such mycophenolate, radiotherapy-but novel biological agents-including tocilizumab-have achieved encouraging results.

Language: Английский

---

Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 132, P. 102898 - 102898

Published: Aug. 24, 2022

Language: Английский

---

Thyroid dysfunction following vaccination with COVID-19 vaccines: a basic review of the preliminary evidence

Journal of Endocrinological Investigation, Journal Year: 2022, Volume and Issue: 45(10), P. 1835 - 1863

Published: March 26, 2022

Language: Английский

---

SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review

Journal of Endocrinological Investigation, Journal Year: 2022, Volume and Issue: 45(6), P. 1189 - 1200

Published: Jan. 29, 2022

Abstract Purpose To perform a systematic review on published cases of subacute thyroiditis (SAT) secondary to SARS-CoV-2 vaccination, highlight main features and increase the awareness this condition. Methods Original reports SAT developed after vaccination (mRNA, viral vector, or inactivated virus vaccines) were retrieved from search electronic databases. Individual patient data demographics, medical history, type vaccine, workup therapies collected. Wilcoxon rank-sum, Kruskal–Wallis chi-squared tests employed for comparisons. Results 30 articles including 48 retrieved, 3 additional evaluated by Authors described included analysis. Of 51 patients, 38 (74.5%) women, median age was 39.5 years (IQR 34–47). Patients 10 days 4–14) vaccine shot. Baseline thyroid exams revealed thyrotoxicosis in 88.2% decreasing at 31.6% follow-up. Corticosteroids used 56.4% treated patients. undergoing non-mRNA vaccines most frequently Asian ( p = 0.019) reported more weight loss 0.021). All patients with previous diagnosis disease belonged mRNA group. Conclusion vaccine-associated is novel entity that should be acknowledged physicians. Previous history may predispose develop vaccines, but further studies larger cohorts are needed verify suggestion. usually mild/moderate severity could easily cases, thus it not raise any concern regarding need vaccinated.

Language: Английский

---

SARS-CoV-2 mRNA Vaccination and Graves’ Disease: A Report of 12 Cases and Review of the Literature

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 107(6), P. e2324 - e2330

Published: March 2, 2022

Abstract Context and objective Thyroid autoimmunity has been reported to be associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the SARS-CoV-2 vaccination recently. We report a series of patients who presented new onset or relapse Graves’ disease-related hyperthyroidism shortly after receiving messenger RNA (mRNA) vaccine at single tertiary institution in Singapore. Methods results describe 12 developed within relatively short interval (median onset, 17 [range, 5-63] days) mRNA vaccine. The majority were females (11/12) median age 35.5 (range, 22-74) years. Six had new-onset hyperthyroidism, whereas other 6 previously well-controlled disease. TSH receptor antibody concentrations ranged from 2.4 32 IU/L. able go for second dose without any further exacerbations. Literature review revealed 21 similar cases across world. Conclusion Our case provides insight into characteristics individuals whom disease was triggered by vaccination. Clinicians need vigilant precipitation exacerbation autoimmune thyroid disorders predisposed exposure Further epidemiological mechanistic studies are required elucidate possible associations between vaccines development autoimmunity.

Language: Английский

---

SARS-CoV-2 Vaccine–induced Thyroiditis: Safety of Revaccinations and Clinical Follow-up

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 107(5), P. e1823 - e1834

Published: Feb. 1, 2022

Abstract Context The number of reported cases with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine–induced subacute thyroiditis (SAT) and Graves’ disease (GD) is growing. However, active debate continues about managing such side effects the safety repeat or booster doses vaccines in cases. Objectives This study aims to present long-term clinical follow-up SARS-CoV-2 SAT GD provide data regarding revaccinations. Methods Patients diagnosed were included. Data outcomes vaccinations documented. literature, including GD, was reviewed. Results Fifteen patients 4 Pfizer/BioNTech COVID-19 vaccine (BNT162b2) associated symptoms a majority all GD. Median time from vaccination symptom onset 7 11.5 days, respectively, while 2 required medical treatment groups, respectively. Remission documented 10 patients, median remission weeks. No exacerbation/recurrence occurred 9 who received dose, worsened following second None experienced that could be Conclusions Revaccinations appear safe cases, more evidence needed

Language: Английский

---

Relapsed and newly diagnosed Graves’ disease due to immunization against COVID-19: A case series and review of the literature

Journal of Autoimmunity, Journal Year: 2022, Volume and Issue: 128, P. 102809 - 102809

Published: Feb. 24, 2022

Language: Английский

---

Current Evidence in SARS-CoV-2 mRNA Vaccines and Post-Vaccination Adverse Reports: Knowns and Unknowns

Diagnostics, Journal Year: 2022, Volume and Issue: 12(7), P. 1555 - 1555

Published: June 26, 2022

The novel mRNA vaccinations against COVID-19 are gaining worldwide attention for their potential efficacy, as well the diagnosis of some post-vaccination-reported adverse reactions. In this state-of-the-art review article, we present current evidence regarding mainly spontaneous allergic reactions, skin occurrences, vascular, blood, endocrine and heart events, respiratory reports, gastrointestinal, hepatic kidney reproductive pregnancy issues muscle ear, eye, neurologic psychiatric events following vaccination COVID-19. We further strategies, provide important information side effects associated with spike protein based LNP-mRNA vaccine its adjuvants, all possible dangerous roles protein, discuss our expert opinion on knowns unknowns towards topic.

Language: Английский

---

The mRNA-LNP vaccines – the good, the bad and the ugly?

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Feb. 8, 2024

The mRNA-LNP vaccine has received much attention during the COVID-19 pandemic since it served as basis of most widely used SARS-CoV-2 vaccines in Western countries. Based on early clinical trial data, these were deemed safe and effective for all demographics. However, latest data raise serious concerns about safety effectiveness vaccines. Here, we review some efficacy identified to date. We also discuss potential mechanism observed adverse events related use whether they can be mitigated by alterations this approach.

Language: Английский

---